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Abstract
The demand for measurement of vitamin D metabolites for clinical diagnosis and to advance our understanding of the role 
of vitamin D in human health has significantly increased in the last decade. New developments in technologies employed 
have enabled the separation and quantification of additional metabolites and interferences. Also, developments of immuno-
assays have changed the landscape. Programmes and materials for assay standardisation, harmonisation and the expansion 
of the vitamin D external quality assurance scheme (DEQAS) with the provision of target values as measured by a reference 
measurement procedure have improved standardisation, quality assurance and comparability of measurements. In this article, 
we describe developments in the measurement of the commonly analysed vitamin D metabolites in clinical and research 
practice. We describe current analytical approaches, discuss differences between assays, their origin, and how these may be 
influenced by physiological and experimental conditions. The value of measuring metabolites beyond 25 hydroxyvitamin D 
(25(OH)D), the marker of vitamin D status, in routine clinical practice is not yet confirmed. Here we provide an overview 
of the value and application of the measurement of 1,25 dihydroxyvitamin D, 24,25 dihydroxyvitamin D and free 25OHD 
in the diagnosis of patients with abnormalities in vitamin D metabolism and for research purposes.
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Introduction
Since the publication of our previous review, [1] there has 
been an ever increasing demand for the measurement of 
vitamin D metabolites. The technology employed to make 
measurements has changed and some additional metabolites 
have appeared that have useful but currently limited roles 
in clinical diagnosis but are improving our understanding 
of vitamin D metabolism. In this article, we will outline 
the developments in the measurement of several analytes 
and discuss the current approaches to the measurement of 
several major vitamin D metabolites. The possible role of 
Free 25 hydroxyvitamin D (25(OH)D) will be explored, 
and the importance of the programmes that are improving 
standardisation of measurements and the quality assurance 
of the measurements made will be discussed. Vitamin D 
metabolite measurements remain a challenge and as a recent 
international conference concluded despite great advances in 
our appreciation of vitamin D metabolism, measurements, 
biological actions on classical and non-classical tissues, and 
therapeutics, much more work remains to be done so that our 
knowledge base can become even more secure [2].
The value of measuring metabolites beyond 25(OH)D, 
like 1,25 dihydroxyvitamin D (1,25(OH)2D), and 24,25 
dihydroxyvitamin D (24,25(OH)2D) is not yet confirmed. In 
some complicated cases, these metabolites may provide the 
information needed for an accurate diagnosis. The problem 
is knowing when to measure, what to measure and how to 
measure. For 25(OH)D, the most frequently used automated 
immunoassays do not meet the requirements of today’s 
standards for certain patient groups and liquid chromatog-
raphy-tandem mass spectrometry is the desired method of 
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choice in these individuals. The less frequently measured 
1,25(OH)2D metabolite enables us to identify a number of 
conditions, including 1α-hydroxylase deficiency, hereditary 
vitamin D-resistant rickets and a number of granulomatous 
diseases or lymphoproliferative diseases accompanied by 
hypercalcaemia. 1,25(OH)2D measurement can help dis-
criminate between the FGF23-mediated and non-FGF23-
mediated hypophosphatemic syndromes. The 24,25(OH)2D 
metabolite has proven its value in the diagnosis of idiopathic 
infantile hypercalcaemia (IIH) and has the potential of hav-
ing value in identifying other diseases. For both metabo-
lites, the understanding of the origin of differences between 
assays is limited and requires further attention. Appropriate 
measurement of vitamin D metabolism in the clinical labora-
tory hinges on comprehension of the value of the different 
metabolites, and the importance of the choice of method 
used to perform the measurements.
Immunoassays for 25(OH)D
Several developments in immunoassays have taken place, 
particularly in the automated assays. Manufacturers have 
tried to address the problems of specificity and sensitiv-
ity with several different approaches. Different methods 
of measurement have been tried, new reagents have been 
employed, and re-standardisation of assays has taken place. 
These approaches have had variable success. The perfor-
mance of many assays is classified as “acceptable in the 
clinical setting” but in truth, some of the assays continue to 
demonstrate under-recovery of 25(OH)D2, cross-reactivity 
with vitamin D metabolites and variable bias in the vitamin 
D External Quality Assessment Scheme (DEQAS). Harmo-
nisation remains an important goal for all assays but is yet to 
be universally achieved.
Abbott has introduced different generations of its fully 
automated assay and has standardised using the NIST Stand-
ard Reference Material (SRM) 2972 material. One evalua-
tion reported CVs ≤ 6.2% for all levels of the controls, with 
between-run uncertainties ≤ 0.36 (expanded to ≤ 0.98 with 
the inclusion of past generations of reagent) [3]. However, 
Annema et al. [4] reported a negative bias of ≤ 17.4% in the 
re-standardised Abbott Architect 25(OH)D assay compared 
with the LC–MS/MS method in samples from vitamin D 
insufficient (< 50 nmol/L) subjects, and in those on vitamin 
D supplement. Further comparison with the Roche assay 
showed the Abbott assay underestimated 25(OH)D concen-
trations in insufficient subjects by up to 17.1% and overesti-
mated in supplemented subjects.
The DEQAS scheme has reported the effects of endog-
enously added metabolites to samples evaluated by sev-
eral assays [5]. The ability of the four commonly used 
automated immunoassays to cross-react with 25(OH)D2 
was reported in an evaluation of vitamin D2 supplemented 
healthy adults [6]. Freeman et al. reported in a comparison 
study with ID–LC–MS/MS method, and all four immuno-
assays showed negative biases (Siemens ADVIA Centaur 
− 7.1%; DiaSorin LIAISON − 15.3%; Roche ELECSYS 
− 8.4%; Abbott ARCHITECT − 16.3%) in samples contain-
ing 25(OH)D2 and 25(OH)D3, reflecting the varying degree 
of antibody cross-reactivity with the D2 metabolite. Wyness 
and Straseski evaluated six automated immunoassays (Beck-
man Coulter Access2 and UniCel DxI 800, Abbott ARCHI-
TECT i2000SR, Siemens ADVIA Centaur XP, DiaSorin 
Liaison XL and Roche MODULAR E170) also concluded 
under-recovery of 25(OH)D in comparison to LC–MS/MS, 
with three of six immunoassays affected by the presence 
of 25(OH)D2. Only two of six immunoassays satisfied the 
recommended bias criteria of < 5% [7]. Dowling et al. had 
reported over-estimation of 25(OH)D measurements in the 
Roche assay due to the cross-reactivity of 24,25(OH)2D pre-
sent in the samples [8]. Karvaly et al. had demonstrated the 
extent of the discrepancies between seven different meth-
ods on the interpretation of vitamin D status and found the 
DiaSorin Liaison had identified significantly more hypovi-
taminosis cases, whereas fewer cases were detected by IDS-
iSYS D assay [9]. Disparity can also occur in specific popu-
lation groups; Hara et al. had reported falsely high 25(OH)
D in serum samples from in infants and postpartum women 
produced by the Diasorin radioimmunoassay (RIA). A con-
stant, disproportional positive bias was found in RIA results 
compared with LC–MS/MS [10].
A large number of immunoassay evaluations and compar-
isons exist in the literature. A small sample of these reports 
has been included in this review to demonstrate that there are 
significant differences in what authors feel is “acceptable” 
performance. While correlation coefficients and CVs are 
often deemed acceptable, it is clear that in certain clinical 
situations and when vitamin D2 is an exogenous supplement 
current immunoassays can give results that are inaccurate 
and could be misleading with over and underestimation 
of deficiency/sufficiency based on current definitions. It is 
important that users know the limitation of their assay and 
recognise when it is necessary to employ other methods of 
vitamin D measurement to obtain the clinically correct inter-
pretation of a subject’s vitamin D status.
Immunoassays for 1,25(OH)2D
Developments in 1,25(OH)2D immunoassays have cen-
tred around the production of fully automated assays. 
The main commercial methods available have been pro-
duced by Diasorin and IDS. The DiaSorin  LIAISON® XL 
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chemiluminescent immunoassay utilises the ligand binding 
domain (LBD) of the vitamin D receptor for the capture of 
1,25(OH)2D molecule, followed by a murine monoclonal 
antibody detection system that recognises the conformation 
change produced by the LBD-1,25(OH)2D complex [11]. 
The method exploits the reaction conditions where bind-
ing differential of VDR highly favours 1,25(OH)2D over 
other forms of hydroxylated vitamin D, and thus negates 
the need for immunoextraction. The Immunodiagnostic Sys-
tems (IDS) iSYS 1,25 VitDXp method involves an onboard 
immunopurification that has been modified from the IDS 
mini-immunocapsule extraction approach. The two-stage 
assay utilises an anti-1,25(OH)2D antibody-coated magnetic 
particles to extract and enrich 1,25(OH)2D in the sample, 
followed by competitive binding against a 1,25(OH)2D-
labelled conjugate with a sheep anti-1,25(OH)2D antibody 
for detection and amplification [12]. Comparison of the IDS-
iSYS assay and other immunoassays found results obtained 
with IDS-iSYS were lower than those obtained with IDS-
RIA by a mean of 20.4% with the following linear regres-
sion equation: iSYS = 0.895 RIA − 8.1. The analysis of 6 
specimens from external quality assessment surveys showed 
means of inaccuracy bias of −14.3%, −0.1%, −11.3% and 
−8.9% in comparison with IDS-RIA (n = 15 laboratories), 
semi-automated iSYS (n = 9), Diasorin-RIA (n = 4) and 
all methods combined (n = 31), respectively [13]. In one 
study comparing the IDS-iSYS, Diasorin LIAISON assays 
and a LC–MS/MS assay there was a marked difference in 
performance reported. The DiaSorin assay performed bet-
ter in terms of accuracy, sensitivity and imprecision com-
pared to the IDS-iSYS assay. Total imprecision was 5.2% 
or less for the DiaSorin assay but reached 20.1% for the 
IDS-iSYS assay. 1,25(OH)2D concentrations measured 
with the DiaSorin assay showed a strong correlation with 
1,25(OH)2D levels measured by LC–MS/MS and a good 
agreement with method-specific means of DEQAS samples. 
By contrast, the IDS-iSYS test overestimated 1,25(OH)2D 
concentrations in human serum, particularly at higher con-
centrations [14].
Reference ranges have been established using immu-
noassays in healthy adults and patient groups [15, 16], but 
wide intervals reported cast concerns over assay specificity, 
given circulating concentration is tightly regulated. Higgins 
et al. [17] reported high disparity between the DiaSorin 
and LC–MS/MS methods in pooled neonates and infants 
samples with elevated 1,25(OH)2D; a positive bias of up 
to 26.5% was observed in immunoassay results, and 3-epi-
1,25(OH)2D was ruled out as a potential source of bias.
25(OH)D by LC–MS/MS
The marked increase in vitamin D workload, significant 
financial constraints and reduction, plus deskilling of the 
laboratory workforce, has seen many hospital laborato-
ries swapping their “gold standard” LC–MS/MS method-
ologies, for more convenient high-throughput automated 
immunoassays despite the problems of immunoassays 
highlighted above. Increased regulatory requirements for 
validation, audit and traceability of “In-house” developed 
methods demanded by national and international regula-
tory authorities have helped drive this move.
Recently, in attempts to address the issues related to 
LC–MS/MS technology, several of the mass spectrometry 
vendors have invested significant resources in developing 
and validating their “total solution”, to varying levels of 
success, complexity and completeness. Waters introduced 
their MassTrak Vitamin D Solution that is CE-marked in 
accordance with IVD Directive 98/79/EC per Annex III 
EC Declaration of Conformity, validated for use with the 
Waters ACQUITY  UPLC® I-Class/Xevo TQD IVD System 
only and the sample preparation has been performed using 
the Tecan Freedom 100/4  EVO® Offline Automated Liquid 
Handling system. However, this has not been commer-
cialised in the US market. The MassTrak Vitamin D Kit 
includes quality control reference materials and calibra-
tions that are traceable to SRM 2972, aiding compliance 
with ISO 15189 guidelines, with a reported CV of ≤ 6.1% 
(range 4.1 to 6.1%) for 25(OH)D2 and ≤ 6.8% (range 3.9 to 
6.8%) for 25(OH)D3, with a reportable range of 10 nmol/L 
to 375 nmol/L for both 25(OH)D2 and 25(OH)D3 [18]. 
Individual reagents and components are available. How-
ever, any change from the way the kit is validated consti-
tutes off label use.
SCIEX followed a similar route, utilising their Class 1 
Medical Device mass spectrometer-based IVD Topaz™ plat-
form integrated with the Topaz Prep Station [19]. Coupled 
with the SCIEX Vitamin D 200M Assay Kit, this has been 
FDA approved (via the de novo pathway) and available in 
the US only. NIST traceable standardisation with reported 
measuring ranges of 2.0 to 165 ng/mL (5.0–412.5 nmol/L) 
for 25(OH)D2 and 2.0 to 160 ng/mL (5–400 nmol/L) for 
25(OH)D3 with reproducibility CV of 4.2 to 6.1% for total 
25(OH)D. Unlike the MassTrak solution, the Vitamin D 
200M assay does not suffer from potential interference from 
3-epi-25(OH)D2 and 3-epi-25(OH)D-3.
Both Waters and SCIEX offer “closed” assays that are 
run on “Open” access IVD platforms. The recently launched 
Thermo Scientific Cascadion™ SM Clinical Analyser is a 
fully automated “closed” random access CE-marked IVD 
device utilising LC–MS/MS, with online sample process-
ing and TurboFlow technology interfaced to a tandem mass 
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spectrometer via a duplex interface resulting in a throughput 
of 25 samples per hour. However, the system is currently 
only available for use outside of the US. Again, this has 
NIST aligned calibration and is free from potential epimer 
interferences with a reportable range of 5.6 to 423.8 nmol/L 
for 25(OH)D2 and 6.5 to 433.9 nmol/L for 25(OH)D3. 
Reported total precision for 25(OH)D2, 25(OH)D3, and total 
25(OH)D are ≤ 6.1%, ≤ 7.6%, and ≤ 7.6%, respectively [20].
It remains to be seen if such a radical approach to more 
LC–MS/MS assays, despite the inherent resource and 
financial support required to accomplish full validation and 
acceptance on a global scale will see a move away from 
“quick, easy and cheap” automated immunoassay systems. 
Interfacing to automated multidisciplinary tracking systems 
has to be an ultimate goal.
For those laboratories still determined to develop and 
validate their own “In-house” 25(OH)D LC–MS/MS and/
or metabolite profile methods, there are now NIST assigned 
ethanolic solutions and frozen human serum-based Stand-
ard Reference Materials (SRMs) available. Consequently, 
NIST/CDC aligned commercial calibration materials have 
also become available, as outlined in the following sections. 
However, there are still none available for 1,25(OH)2D2, 
1,25(OH)2D3, 24,25(OH)2D2 or 3-epi-25(OH)D2 and it is a 
similar picture with the DEQAS scheme. These vitamin D2 
metabolites are not currently at the vanguard of routine clini-
cal practice and generally at low concentrations. As LC–MS/
MS assay specificity and sensitivity continue to improve, 
accurate quantitation of these minor metabolites may help 
in our understanding of the “unusual” clinical presentation.
Generally, LC–MS/MS quantification of vitamin D 
metabolites using triple quadrupole unit mass resolution 
instruments is the mainstay in clinical laboratories. The 
relatively recent introduction of bench-top high-resolution 
mass spectrometer instruments (Orbitrap MS and quadru-
pole time-of-flight MS) now offers the possibility of routine 
quantification of vitamin D metabolites using accurate mass, 
whilst also acquiring potentially important additional quali-
tative information from full scan acquisitions [21].
Quality Assurance and Standardisation 
of 25(OH)D Assays
Absolute and relative bias between different methodologies 
and within methods between different laboratories has been 
reported in the past [22]. In the last 10 years, much pro-
gress has been made to reduce bias and enable comparability 
between laboratories through the Vitamin D standardisation 
programme (VDSP) [22]. Recently, 15 clinical and research 
laboratories participated in an inter-laboratory comparison 
study coordinated by the VDSP; nearly all LC–MS/MS 
results achieved VDSP criteria (CV ≤ 10% and mean bias 
≤ 5% against NIST RMP/Ghent University), whereas only 
50% of immunoassays met the criterion for a ≤ 10% CV and 
only three of eight immunoassays achieved the ≤ 5% bias 
[23]. It is now widely accepted that a standardised measure-
ment of 25(OH)D is a LC–MS/MS method that is aligned 
to NIST RMP, with quality assurance certified by DEQAS. 
In 2013, DEQAS had changed to an accuracy-based scheme 
with the NIST RMP. In 2017, NIST has released SRM 
972a Vitamin D Metabolites in Frozen Human Serum as a 
replacement for SRM 972. The four levels of SRM 972a are 
composed of unmodified human serum and have been certi-
fied by three isotope-dilution mass spectrometry methods 
performed at NIST and at the CDC. The reference values 
include the 25(OH)D2, 25(OH)D3 and 3-epi-25(OH)D3 
[24]. In addition, NIST issued a new high level SRM 2973 
in frozen human serum, with assignment values of around 
100 nmol/L to complement SRM972a [25]. From 2018, 
DEQAS target values were generated by the Nutritional Bio-
markers Laboratory at the Centers for Disease Control and 
Prevention (CDC). The scheme has been further improved 
with the introduction of uncertainty values attached to each 
distribution sample [26]. Starting with the 2019 distribu-
tion cycle, the calculated total measurement uncertainty will 
allow DEQAS participants to determine their agreement and 
traceability to the NIST RMP.
Standardisation of 25(OH)D assays has begun to show 
an impact on the estimation of the prevalence of vitamin D 
deficiency on a global scale. A VDSP study applied their 
standardised protocol to existing 25(OH)D values from 14 
European population studies had found 13% of the 55,844 
European individuals had serum 25(OH)D < 30 nmol/L on 
average in the year, and 40.4% had 25(OH)D < 50 nmol/L. 
The high prevalence of vitamin D deficiency across the vast 
geographical footprint represents a major public health con-
cern on an alarming scale [27].
Free 25(OH)D
The majority of vitamin D and its metabolites circulate 
in plasma bound to vitamin D binding protein (VDBP) 
(~ 85–90%) and to a lesser extent and with a lower bind-
ing affinity to albumin. Less than 1% circulates in its free 
form [28–30], i.e. for 25(OH)D, free concentrations are in 
the picomolar range and for 1,25(OH)2D in the femtomolar 
range [29–33]. The free hormone theory states that only the 
free fraction can enter cells. This may however not fully 
apply to 25(OH)D since several organs express a megalin-
mediated internalisation mechanism for VDBP-bound 
metabolites. The free and total 25(OH)D concentrations in 
healthy people are strongly correlated [29, 30, 34, 35]. Spe-
cific physiological and pathological conditions are associ-
ated with alterations of plasma VDBP and the relationship 
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between total and free 25(OH)D, such as renal and liver 
disease and pregnancy [31, 36]. The impact of these varia-
tions on tissue 25(OH)D availability is unclear. Compared 
to total 25(OH)D, free 25(OH)D has been reported to be 
more strongly associated with PTH, bone mineral density 
(BMD) and various non-skeletal or calcaemic outcomes (e.g. 
risk of various types of cancer) in some but not all reports. 
This was recently reviewed by Bikle et al. [36]. There is also 
conflicting evidence regarding racial differences in the total 
to free 25(OH)D ratio. These findings may be confounded 
by methodological issues in one of the VDBP assays used, 
resulting in pronounced differences in VDBP concentrations 
between VDBP genotypes [30, 37].
There are several methods in use to obtain the value for 
free 25(OH)D and 1,25(OH)2D concentration: they are 
either calculated or directly measured, the results of which 
can vary [29, 30, 38].
Direct Measurement of Free 25(OH)D
There are currently no assays for the direct measurement of 
the free fraction of any other metabolite than 25(OH)D. The 
only assay for free 1,25(OH)2D was based on centrifugal 
ultra-filtration [33] and is now no longer in operation (per-
sonal communication Bikle).
Two assays for the direct measurement of free 25(OH)
D have been described. The first method was developed by 
Bikle and is based on centrifugal ultra-filtration [32]. The 
second is an immunoassay (Future Diagnostic, Wijchen, The 
Netherlands [39]). A third assay for the measurement of bio-
available 25(OH)D was described by Powe et al. [40], but 
no reports using this assay have been published. Currently, 
only the Future Diagnostic assay is commercially available 
and is widely used. The methodology and validation of this 
assay is briefly summarised below.
The assay free 25(OH)D enzyme-linked immunosorbent 
assay (ELISA) is a 2-step immunoassay using a 96-microti-
tre plate coated with a 25(OH)D antibody, specific for free 
25(OH)D. After addition of sample and incubation to allow 
binding of free 25(OH)D, the plate is washed and bioti-
nylated 25(OH)D is added. This will bind any unoccupied 
25(OH)D antibody. After unbound biotinylated 25(OH)D 
is removed, the amount of antibody bound to biotinylated 
25(OH)D is quantified by adding streptavidin peroxidase 
and subsequently 3,3′,5,5′-tetramethylbezidine chromog-
enic substrate. Bound streptavidin peroxidase is quantified 
spectrophotometrically with a plate reader at a wavelength of 
450 nm. This method has a measurement range of 2.4–35 pg/
mL and a limit of detection of 2.4 pg/mL. Cross-reactivity 
with free 25(OH)D2 (77%) is lower than for 25(OH)D3 [39]. 
The accuracy of this assay was evaluated against a dialyses 
method (although this latter method itself was not validated, 
and there may be substantial issues with the use of dialysis 
for 25(OH)D [36]). However, also a comparison of results 
with the free 25(OH)D ELISA with the well-validated dialy-
ses method as developed by Bikle provided similar results 
in samples from patients with conditions altering the % free 
to total 25(OH)D [36]. A proof of principle experiment was 
conducted by spiking samples with VDBP and albumin. 
This, as expected resulted in a significant reduction in the 
measured free 25(OH)D concentration in the free 25(OH)D 
[39]. To date, no quality assurance scheme, standard mate-
rial or standardisation programme exists for free 25(OH)D 
assays. Generation of data on inter-laboratory comparability 
for the free 25(OH)D ELISA is underway.
Calculated Free 25(OH)D and 1,25(OH)2D
Algorithms for the calculation of the free concentrations 
are based on the concentrations of vitamin D metabolites 
and those of VDBP and albumin. Others calculate the bio-
available fraction, which equates to only the fraction not 
bound to VDBP and assumes the fraction bound to albu-
min and [41] other lipoproteins is bioavailable [40, 42]. A 
number of other authors have employed the ratio between 
VDBP and 25(OH)D [41, 43]. In most reports, the algorithm 
employed a constant binding affinity of VDBP and albumin 
for the vitamin D metabolite. These binding affinities were 
derived from Scatchard analyses [32, 36]. Other algorithms 
incorporate a VDBP genotype-specific binding affinity [44], 
although the validity of VDBP-specific affinity constants has 
been debated [36, 45]. Also, the assumption that the binding 
affinity of VDBP and albumin remains constant under all 
physiological and pathological conditions may not be valid 
as discrepancies between directly measured and calculated 
free 25(OH)D were reported in pregnant women and liver 
disease [31].
Since the calculated free concentration is dependent on 
a composite of biochemical measurements, it relies on the 
accuracy of all of these measurements. Particular in the 
measurement of VDBP there is substantial variation between 
different methods. There are many different VDBP assays in 
use. Most commercially available assays are immune meth-
ods and thus dependent on antibody binding. Methods use 
either mono- or polyclonal antibodies. Polyclonal sera tend 
to include a variety of antibodies that react to a larger panel 
of epitopes of VDBP. In contrast to polyclonal antibody-
based immune assays, assays using monoclonal antibodies 
typically result in different plasma VDBP concentrations 
across VDBP genotypes, dependent on the affinity of the 
antibody for the VDBP genotype. This is also not observed 
with quantification of VDBP by LC–MS/MS [30, 37, 46]. 
To date, no quality assurance scheme, standard material or 
standardisation programme exists for VDBP. This has led to 
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substantial variation in the reported VDBP values and sub-
sequently in calculated free 25(OH)D concentrations and to 
discrepant findings and conclusions [30, 36]. These technical 
limitations have limited the research into the kinetics and 
role of the free fraction of vitamin D metabolites.
24,25(OH)2D
Measurement of serum 24,25(OH)2D was first reported in 
the late 1970s using competitive protein binding assays 
[47, 48] in animal and in vitro models to study the heal-
ing properties of 24,25(OH)2D on bone [49]. When HPLC 
methods with UV detection became the method of choice 
for 25(OH)D, the improvement in assay sensitivity had 
remained insufficient to detect serum 24,25(OH)2D, which 
circulates at concentrations around 10-fold lower than 
25(OH)D. Shimizu et al. first reported a chemical deriva-
tisation method for 24,25(OH)2D using a Cookson-type 
dienophilic agent. It reacts to the s-cis-diene moiety of 
vitamin D via the Diels–Alder reaction, forming a conju-
gated diene derivative for detection by HPLC with a fluo-
rometric detector [50]. However, despite the improvement 
in assay sensitivity, studies in the 1980–1990s have found 
limited biological activity of 24,25(OH)2D in humans 
[51–53], and it was considered to be an inactive catabolic 
product of the vitamin D pathway [54]. The revival of 
interest in 24,25(OH)2D measurement was brought about 
after Genome-wide studies have pinpointed CYP24A1 
as one of the major genetic determinants of variability 
in 25(OH)D [55]. Publications have shown CYP24A1 
defects in children with IIH [56], in adults with nephro-
lithiasis and nephrocalcinosis [57], and in patients with 
chronic kidney disease [58] are associated with low serum 
24,25(OH)2D concentration, and the genetic defect can 
be highlighted by an elevated 25(OH)D:24,25(OH)2D 
vitamin D metabolite ratio (VMR). The introduction of 
LC–MS/MS in clinical laboratory has enabled stand-alone 
measurement of 24,25(OH)2D, or in a profile analysis 
with 25(OH)D and 1,25(OH)2D to be performed in spe-
cialist laboratories. The use of a derivatisation agent has 
remained an essential step, especially when analysed using 
entry-level to mid-range LC–MS/MS systems. The most 
commonly described derivatisation agents for vitamin D 
metabolites in the literature (reviewed in [59]) are based 
on a substituted form of 1,2,4‐triazoline‐3,5‐dione (TAD) 
at the 4-position (4-X-TAD). The Diels–Alder reaction is 
stable, robust, can be performed under ambient conditions 
and terminated by the addition of water. TAD derivatisa-
tion adds proton-affinitive oxygen and nitrogen molecules 
to the structure of vitamin D, thus increasing ionisation 
potential. It also shifts the compound to a higher mass 
range, where background interference from low molecular 
weight species is relatively low. Non-derivatised methods 
require high-end LC–MS/MS instruments due to the poor 
ionisation efficiency of vitamin D metabolites, and often 
resort to the use of water loss precursor ions at low colli-
sion energy [60], which can be susceptible to interference 
by pseudo-molecular ions. It is important to note the dif-
ferent properties of the derivatisation agents; DMEQ-TAD 
(4‐[2‐(3,4‐dihydro‐6,7‐dimethoxy‐4‐methyl‐3‐oxo‐2‐qui-
noxalinyl)ethyl]‐TAD) forms two separate peaks for the 
R- and S-stereoisomers, and allows chromatographic sepa-
ration of 23,25(OH)2D and 25,26(OH)2D [61]; DAP-TAD 
(4-4′-dimethylaminophenyl-TAD) [62] and Amplifex™ 
Diene [63] can achieve baseline separation of C3-epimers, 
whereas 2-nitrosopyridine can form distinct precursor and 
product ions for 24,25(OH)2D and 1,25(OH)2D [64] and 
thus increases assay selectivity. The majority of derivati-
sation agents are commercially available in ready to use 
powder or in the precursor forms. The improvement in 
sensitivity and specificity enable differential analysis of 
vitamin D metabolites, expanding the applicability in 
research and diagnostic investigations.
Measurement of serum 24,25(OH)2D is now available in 
specialist laboratories. Reference intervals between 1.1 and 
13.5 nmol/L in a healthy population have been reported by 
the authors of this paper [65], and in others alike [66–68]. 
The serum concentration of 24,25(OH)2D is positively cor-
related with 25(OH)D; evidence had shown 24,25(OH)2D 
to be an excellent surrogate predictor of vitamin D defi-
ciency [65, 69, 70]. However, seasonal changes affect 
serum concentration in a manner similar to 25(OH)D. 
Macdonald et al. reported a 2-fold increase in peak sum-
mer months (July–August in UK) in a longitudinal study 
[71]. The biological function of 24,25(OH)2D has yet to be 
elucidated; research studies have shown evidence in promot-
ing fracture healing and protection against cartilage dam-
age [72–75]. In clinical settings, 24,25(OH)2D measure-
ment is best utilised when expressed in a ratio with 25(OH)
D, where 25(OH)D:24,25(OH)2D VMR can indicate the 
vitamin D catabolic status of an individual and highlight 
24-hydroxylase deficiency due to genetic abnormalities of 
CYP24A1. In a healthy population, 25(OH)D:24,25(OH)2D 
VMR is between 7 and 23, and increases when vitamin D 
status becomes insufficient [65]. A ratio of > 80 is asso-
ciated with patients with heterozygous or biallelic muta-
tions of CYP24A1 [67, 69]. Moderate elevation of 25(OH)
D:24,25(OH)2D VMR due to partial inactivity of CYP24A1 
is associated with renal impairment [58, 76] and bone disor-
ders [77]. 25(OH)D:24,25(OH)2D VMR has an advantage 
for being less susceptible to seasonal fluctuation [78], allow-
ing interpretation using fixed reference intervals irrespective 
of the time of the year.
Measurement  of  24,25(OH)2D and 25(OH)
D:24,25(OH)2D VMR has shown potential in optimising 
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treatment response to vitamin D supplementation. The 
increased incidents of falls and fractures in the older popu-
lation associated with the use of ultra-high doses of vitamin 
D administered annually or monthly [79, 80] suggests the 
correlation of risks vs benefit effects of vitamin D exhibit 
a U-shaped curve, rather than a J-shaped curve. Although 
higher doses of vitamin D supplement were more effective 
in reaching 25(OH)D concentration of 50 nmol/L, high sup-
plementation levels can be detrimental to the patients. A 
common strategy to correct vitamin D deficiency replace-
ment is a loading dose followed by a daily maintenance dose, 
which can be optimised based on the characteristics of the 
patient, in combination with baseline profile of 25(OH)D, 
24,25(OH)2D measurements and VMR. Future research 
should aim to establish the appropriate dose and frequency 
of administration to achieve an increase in 25(OH)D while 
limiting the disproportional increase in 24,25(OH)2D con-
centrations. The use of VMR can provide insight that may 
begin to explain the lack of optimal response to increasing 
supplementation with vitamin D.
Efforts to standardise and improve inter-laboratory com-
parability of 24,25(OH)2D assays are in progress. NIST 
SRM972a and 2973 in frozen human serum are available 
with certified values for 24,25(OH)2D3 between 3.39 and 
7.51 nmol/L [24]. DEQAS has introduced a pilot scheme 
since April 2015, but due to the small number of partici-
pants, albeit using LC–MS/MS methods, high inter-labora-
tory variability was observed, with CVs ranging between 19 
and 29% [81]. Wise et al. reported lower variability between 
five laboratories using isotopically labelled 24,25(OH)2D3 
as internal standard [82]. The availability of reference-
traceable, matrix-matched, multi-point calibration stand-
ards would improve method accuracy and commutability of 
results between laboratories.
1,25(OH)2D by LC–MS/MS
LC–MS/MS methodology for 1,25(OH)2D has remained 
confined to laboratories with high-end instruments. To 
achieve adequate assay sensitivity without derivatisation 
requires extensive sample preparation to enrich sample con-
centration by either a manual immunoaffinity step [83, 84] or 
online two-dimensional chromatography [85, 86]. Chemical 
derivatisation with Cookson-type dienophilic agents is more 
commonly used. Of  those methods described in this review, 
DAP-TAD was reported to produce the best ion potentials 
and assay sensitivity [87]. A LC–MS/MS assay has been 
developed that uses immunoextraction of 0.5 mL serum 
followed by Amplifex™ derivatisation of the dried elu-
ent, with analysis using the SCIEX 6500+ instrument [88]. 
The limit of quantitation was 15 pmol/L and the method 
linear up to 600 pmol/L. Repeatability ranged from 6.1% 
at 23 pmol/L to 2.5% at 172 pmol/L and imprecision was 
15.6% at 26 pmol/L to 8.3% at 173 pmol/L. The method was 
unaffected by icterus, haemolysis or lipaemia. Analysis of 
DEQAS samples demonstrated a negative bias compared 
with the all lab trimmed mean (average − 13.8%) and the 
specific method group (average − 7.75%). A negative bias 
was observed across the concentration range found in 78 
patient samples in comparison to a commercial RIA (mean 
− 47.8%).
Long-term assay performance between all the immu-
noassay and LC–MS/MS methods is closely monitored by 
DEQAS. The lack of cross-assay reference standards has 
yet to be addressed. Since the introduction of the DiaSorin 
method on the Liaison XL platform, the use of manual radi-
oisotopic immunoassays have been on a gradual decline. 
The shift has reduced inter-laboratory variability, but 
raised concern over the dominance of the DiaSorin method 
group amongst the participants in the DEQAS scheme, 
thereby strongly influencing the All Laboratory Trimmed 
Mean (ALTM), potentially masking method-specific bias.
1,25(OH)2D measurements are mostly used in clinical set-
tings or disease-focused patient studies. The use in healthy 
population-based or vitamin D supplementation studies is 
rare; serum concentration does not correlate with 25(OH)D. 
Despite being the most biologically active form of vitamin D 
metabolite, 1,25(OH)2D should not be used for the assessment 
of vitamin D status. Serum level is tightly regulated by the 
hydroxylation enzymes expressed by the actions of CYP27B1 
and CYP24A1, and influenced by PTH and FGF23. The rela-
tionship of 1,25(OH)2D with other vitamin D metabolites 
is best described using VMR; the authors have reported in 
a large population of healthy army recruits, an exponential 
increase in 1,25(OH)2D:24,25(OH)2D VMR when 25(OH)D 
concentration fall below the 50 nmol/L insufficiency threshold 
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Fig. 1  Distribution of PTH under the influence of 
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1,25(OH)2D:24,25(OH)2D VMR increases exponentially with the 
decline of serum 25(OH)D, represented by LOWESS fitted curve 
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(Fig. 1) [78]. The evidence suggests as the availability of 
25(OH)D precursors diminishes, the catabolism of 25(OH)D 
to 24,25(OH)2D is reduced to allow a proportional increase in 
serum 1,25(OH)2D. The finding was supported by a significant 
decrease in the distribution PTH concentration observed in 
individuals with high-low 1,25(OH)2D:24,25(OH)2D VMR 
over low–high 25(OH)D. Understanding the mechanisms con-
trolling the active and catabolic forms of vitamin D metabo-
lites and the interactions with tissue VDR will be the key to 
unlock the role that vitamin D plays in systemic processes 
behind calcium homeostasis, bone physiology, muscle func-
tion, fracture healing and immune response to inflammation 
and infection.
Measurement of Vitamin D Metabolites 
in Tissues and Bodily Fluids Other 
than Plasma
Vitamin D, its metabolites and VDBP have been detected 
and measured in a wide range of human tissues and bodily 
fluids, other than plasma. These include breast milk, urine, 
semen, saliva, cerebrospinal and synovial fluid, skin and 
muscle biopsies and hair samples [89–94]. The collection of 
such samples may provide benefits, such as ease of sample 
collection and avoidance of invasive sampling methods or 
for the investigation of organ-specific aspects of vitamin D 
metabolism and function. Each of these matrixes may require 
specific pre-analytical extraction protocols. In some of these 
sample types, the low concentrations of the analytes of inter-
est may require enrichment to achieve concentrations within 
measurement ranges. Results derived from both immunoas-
says and increasingly, chromatographic techniques have been 
reported. So far, standardisation and quality assurance schemes 
for assays conducted in matrices other than plasma or serum 
are lacking. Also, studies investigating potential interferences 
in assays conducted in these matrices are scarce. With the 
exception of the recognised low concentrations of vitamin 
D and 25(OH)D in human breast milk [94, 95], which has 
informed clinical and population guidance of vitamin D intake 
requirements in infancy (The Scientific Advisory Committee 
on Nutrition [96]), the utility of the measurement of vitamin 
D metabolites and VDBP is so far limited to research settings. 
This research has focussed on the presence and availability of 
vitamin D metabolites and VDBP in order to elucidate the role 
of vitamin D metabolites within specific organ systems, e.g. 
in the investigation of para- and autocrine effects and produc-
tion and catabolism of metabolites. Also, research has aimed 
to provide mechanistic insights in the role or consequences 
of abnormalities in vitamin D status or metabolism in patho-
logical conditions. Discussion of this research and the specific 
analytical challenges associated with this research is beyond 
the scope of this literature review.
Conclusion
Major developments have taken place in the measurement 
of vitamin D metabolites. Advances have been made in the 
measurement of 25 hydroxyvitamin D, the marker of vitamin 
D status and of other metabolites that may inform clinical 
and research practice. The choice of the most appropriate 
methodology depends on its application, required specificity 
and accuracy of measurement and technical and financial 
considerations.
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